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Apoptosis is the enigmatic, physiologic mecha-
nism in which specific cells are programmed for
death to regulate tissue mass and architecture. Kerr
et al,1 in 1972, introduced the word apoptosis (Greek
[origin] meaning “falling off”) into the scientific lit-
erature as a novel concept where cell death occurred
in a suicidal manner. Reported differences in apop-
totic cells, as opposed to necrotic cells included cell
membrane blebbing, clumping of nuclear chromatin,
and nuclear fragmentation. Alterations in the rate of
programmed cell death have been thought to con-
tribute to pathologic processes in a variety of tissues.
Disease processes that involve malignant transforma-
tion, neurologic disorders, heart disease, and
immune deficiency syndrome have been attributed to
both accelerated and decreased rates of apoptosis.2-7
Recent reports have linked apoptosis in human vas-
cular atherosclerosis and large vessel structural
integrity.8-13 To evaluate mechanisms in large vessel
pathologic conditions, we examined the extent of
vascular smooth muscle cell (VSMC) apoptosis in
aneurysmal, occlusive, and normal human aortic tis-
sue. Our objective was to determine whether differ-
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Purpose: Apoptosis is a physiologic mechanism of cell death that regulates mass and archi-
tecture in many tissues. Apoptosis has been described as a feature in human vascular ath-
erosclerosis and large vessel structural integrity. We examined the extent of vascular
smooth muscle cell (VSMC) apoptosis in aneurysmal, occlusive, and normal human aor-
tic tissue.
Methods: Tissue samples of aneurysmal, occlusive, and normal human infrarenal aorta
were evaluated. DNA fragmentation detection methods, immunohistochemistry, and
DNA electrophoresis determined VSMC density, VSMC apoptosis, and apoptosis mark-
ers. Apoptotic cells and VSMC nuclei were counted with the use of computer-generated
image analysis. Aortic subtypes were compared statistically by analysis of variance.
Results: Seventeen aneurysmal, ten occlusive, and five normal human aortas were evalu-
ated. By α1-actin immunostaining, VSMC density was least in aneurysmal aortas (271.8
± 13.5 cells/high-power field [HPF]) compared with occlusive aorta (278.2 ± 39.4
cells/HPF) and normal aortas (291.0 ± 25.4 cells/HPF; P = not significant). Presence
of apoptotic VSMCs was demonstrated by terminal deoxynucleotidyl transferase frag-
ment end labeling and propidium iodide nuclear staining. VSMC apoptosis was greatest
within aneurysmal aortas with 11.7 ± 1.5 cells/HPF compared with occlusive aortas
with 3.3 ± 0.8 cells/HPF (P < .05) and normal aortas with 3.75 ± 4.6 cells/HPF (P <
.05). Significant differences in apoptosis markers, p53 or bcl-2, could not be demon-
strated by immunohistochemistry or DNA electrophoresis in aortic subtypes. 
Conclusion: Apoptosis of VSMCs is increased and VSMC density is decreased within the
medial layer of aneurysmal aortic tissue. Structural degeneration of aortic tissue at the
cellular level contributes to aneurysmal formation. (J Vasc Surg 2000;31:567-576.)
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ences in VSMC apoptosis and apoptosis markers var-
ied between aortic disease subtypes. 
MATERIAL AND METHODS
Tissue preparation. Tissue samples of aorta
were collected intraoperatively from patients who
were undergoing repair for abdominal aortic
aneurysms (AAAs) and aortoiliac occlusive disease.
Grossly normal aorta was harvested from cadaveric
donors who were undergoing organ harvest for
transplantation. All specimens were collected from
the anterolateral section of infrarenal aorta and sec-
tioned accordingly. Aortic tissue sectioned for light
microscopy was placed immediately in 10% neutral
buffered formalin for overnight fixation, transferred
to 70% ethanol, and paraffin embedded by standard
techniques. Aortic tissue for subsequent protein and
nucleic acid extraction was immediately flash frozen
in liquid nitrogen and stored at –70°C. The remain-
ing aortic sections were processed for electron
microscopy by placement in cacodylate buffer with
2.5% glutaraldehyde for 24 hours at 4°C then trans-
ferred to cacodylate buffer. Approval from the
University of Tennessee Investigational Review
Board was obtained for all aortic tissue collection.
Immunohistochemistry. Paraffin-embedded
aortic specimens were cut into 5-µm serial sections
and mounted on positively charged microscope
slides. Tissue samples were cleared and rehydrated
by sequential immersions in three changes of xylene,
followed by baths of 100% ethanol, 95% ethanol,
50% ethanol, and distilled water. Tissue was treated
with Protease 24 (BioGenex, San Ramon, Calif) and
blocked with protein block, containing goat serum
(BioGenex), at room temperature (RT). Specimens
were incubated with the specific antibody for 1 hour
at RT. The mouse monoclonal α-actin antibody
(1:50; Dako Corporation, Carpenteria, Calif) was
used for VSMC immunostaining. Binding of the pri-
mary antibodies was amplified with a biotin-strepta-
vidin system (BioGenex). Immunoreactivity was
observed with an alkaline phosphatase substrate
(Vector Red; Vector Laboratories, Burlingame,
Calif). Staining development was stopped by immer-
sion in tap water, and the slide was counterstained
with Harris hematoxylin. Tissue samples were dehy-
drated and coverslipped with mounting medium. 
For correlation with the quantity of apoptosis
within the aortic tissue, identification of p53 antibody
and bcl-2 was performed. Localization of p53 protein,
wild type and mutant, was accomplished by a citra
buffer retrieval staining protocol. Briefly, tissue sam-
ples were cleared and rehydrated as described earlier.
Slides were rinsed in 0.5% hydrogen peroxide followed
by incubation with 1X Antigen Retrieval Citra
(BioGenex) at 98°C for 15 minutes. After cooling, the
sections were blocked with normal goat serum and
incubated with mouse monoclonal p53 antibody (1
µg/mL; Santa Cruz Biotechnology Inc, Santa Cruz,
Calif) for 20 minutes at RT then overnight fixation at
4°C. Immune complexes were amplified with biotin-
streptavidin/peroxidase (BioGenex), detected with
3,3´-diaminobenzidine substrate (Sigma Laboratories,
St Louis, Mo). Formalin-fixed, paraffin-embedded
infiltrating ductal breast carcinoma sections served as
positive controls for p53. Identification of bcl-2 was
performed with the standard immunohistochemical
techniques described earlier and incubation with
mouse monoclonal anti-human bcl-2 oncoprotein
(1:40; Dako Corporation) for 30 minutes at RT.
Formalin-fixed, paraffin-embedded sections of lymph
node served as bcl-2 positive controls. 
All specimens were also stained with hematoxylin
and eosin for tissue authentication.
Apoptosis assay. Embedded aortic sections
were deparaffinized, rehydrated through graded
alcohol, and treated with proteinase K (20 µg/mL)
at RT. Slides were rinsed in 1X Tris-buffered saline
solution (TBS) and blocked for endogenous peroxi-
dase activity with 3% hydrogen peroxide in
methanol. Equilibration with terminal deoxynu-
cleotidyl transferase buffer for 20 minutes was fol-
lowed by DNA end-labeling with terminal deoxynu-
cleotidyl transferase labeling reaction mixture
(FragEL Assay; Oncogene Research Products,
Cambridge, Mass) at 37°C in a humidifying cham-
ber for 1.5 hours. Labeling reaction was terminated
with 0.5 mmol EDTA and multiple washes in 1X
TBS. For detection, slides were incubated with per-
oxidase streptavidin solution followed by freshly pre-
pared diaminobenzidine substrate in tap water for
12.5 minutes at RT. Slides were rinsed in hydrogen
peroxide, counterstained in methyl-green solution,
and dehydrated. Apoptotic nuclei were identified by
the presence of dark brown staining. Positive con-
trols were generated by application of DNAse (1
µg/mL) in 1X TBS/1 mmol/L MgSO4 for 20 min-
utes at RT after protease incubation. 
Colocalization with DNA end-labeling and sec-
ondary immunohistochemical staining with α-actin
antibody was performed to identify apoptotic cells as
VSMCs. Briefly, DNA end labeling was completed as
described earlier, excluding the counterstain with
methyl green. Tissue sections were then incubated
with mouse monoclonal α-actin antibody (1:25)
overnight at 4°C. Binding of the smooth muscle cell
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antibody was amplified with the use of the biotin-
streptavidin system. Immunoreactivity was observed
with the use of an alkaline phosphatase Vector Red
substrate. Tissue samples were then dehydrated and
coverslipped with mounting medium.
Propidium iodide assay. Paraffin-embedded
tissue sections were rehydrated by xylene and
sequential alcohol immersions. Tissue was incubated
with propidium iodide (PI; 50 µg/mL) in phos-
phate-buffered saline solution and 0.1% bovine
serum albumin for 30 minutes at 37°C. Sections
were washed in phosphate-buffered saline solution,
dehydrated, and coverslipped. Positive-staining cells
for apoptosis were identified under fluorescent
microscope as bright orange condensed or frag-
mented nuclei.
Protein isolation of p53. Frozen aortic tissue
was sliced thinly and placed in lysis buffer (1%
Monodet 40, 1% Triton X, 0.01% sodium dodecylsul-
fate, 1% sodium deoxycholate, 150 mmol/L Tris, 1
mmol/L EDTA, 50 mmol/L nafcillin, 1 mmol/L
sodium pyrophosphate, 1 mL/gm of tissue). After
the addition of proteases, tissue samples were further
homogenized at 0°C with 30 mL phenylmethylsul-
fonyl fluoride stock per 3 mL of homogenate and
centrifuged twice at 15,000g for 20 minutes. Protein
quantification was determined with the use of a Sigma
Diagnostic Protein Assay kit (Sigma Laboratories).
Twenty-five micrograms of denatured protein was
electrophoresed on a 4% to 20% Tris-glycine gel.
Protein was transblotted to positive-charged nitrocel-
lulose. The membrane was blocked with 5% milk
solution and incubated with mouse monoclonal p53
antibody (0.5 µl/mL; Santa Cruz Biotechnology
Inc). The membrane was washed, and the immune
complexes were linked with goat anti-mouse antibody
conjugated with horseradish peroxidase. The nitrocel-
lulose was washed and detected with a Pierce Super
Signal Chemiluminescence detection kit (Pierce,
Rockford, Ill). After a brief exposure to Amersham
Hyperfil ECL (Amersham Life Science Inc, Arlington
Heights, Ill), p53 protein was visualized in positive
control lane (MCF-7 cell lysate). 
Analysis. Analysis of the immunohistochemical
characteristics was performed with a computer-gener-
ated image analysis. Slides were examined by light
microscopy under ×100 to ×400 magnification (Zeiss
Axioskop; Carl Zeiss Inc, Thornwood, NY), transmit-
ted with a charge-coupled discharge color television
camera to an image monitor. Interpretation of images
was processed with Zeiss Image software (version 3.0;
Carl Zeiss Inc). All specimens were reviewed by an
independent pathologist to confirm tissue-staining
authenticity. Staining characteristics (such as localiza-
tion, distribution, and quantity of apoptotic cells)
were determined for each sample. Four random mea-
surement sites were identified within the appropriate
staining area and calculated per sample. The average
density medial VSMC of each specimen was deter-
mined by a count of the number of α-actin positive
cells over four random ×100 power fields. Mean
apoptotic cells within the medial layer (identified as
brown staining cells) were calculated in a similar man-
ner under ×200 power fields. Staining specifications
of the specimens were compared by aortic subtype
with the one-way analysis of variance by the Student-
Newman-Keuls method and Dunn’s test (SigmaStat;
Jandel Corporation, San Rafael, Calif).
RESULTS 
Seventeen aneurysmal, ten occlusive, and six nor-
mal human aortas were evaluated. Patients with rup-
tured, thoracoabdominal, or inflammatory aneurysms
were excluded from the study. The average size of the
AAAs before operation measured 5.9 cm (range, 4.2-
9.0 cm). The average age was 71.5 years (range, 55-
87 years) for patients with AAA, 50.8 years (range,
28-63 years) for patients with occlusive aortas, and
45.5 years (range, 34-64 years) for organ donors. All
specimens used in the study had a storage time of less
than 12 months. 
Staining characteristics. α1-Actin antibody
immunostaining confirmed the predominance of
VSMC in the medial layer of all aortic tissue types
(Fig 1). Consistent with previous reports by other
investigators, the architecture of the medial layer of
aneurysmal aortas exhibited a more disrupted and
disorganized pattern of VSMCs than normal or
occlusive aortas.12,14-16 Cellular staining for α1-actin
antibody was concentrated in the perinuclear region
of the VSMCs. Aneurysmal aortas consistently
revealed fewer VSMCs within the medial layer com-
pared with occlusive and normal aortas. The mean
VSMC count was 271.8 ± 13.5 cells/high-power
field (HPF) for aneurysmal aortas, compared with
278.2 ± 39.4 cells/HPF for occlusive aortas and
291.0 ± 25.4 cells/HPF for normal aortas (Figs 2-4)
(Table I). No statistical significance difference was
seen for multiple comparisons of aortic subtypes.
Apoptotic cells were visualized within the aortic
medial layer with DNA end-labeling methods and PI
nuclear staining. Obvious endothelial-cell apoptosis
was not apparent. VSMC apoptosis was transmural
in nature and not inherent to any particular anatom-
ic portion of the medial layer (Fig 5). Apoptotic cells
appeared homogeneously throughout tissue sections
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and not pocketed to particular segments.
Colocalization staining methods demonstrated α-
actin staining in the perinuclear portion, and the
dark-staining condensed nuclei of apoptotic cells
were confirmed to be VSMCs (Fig 6). PI nuclear
staining was added to verify the presence of apop-
totic cells. Positive PI-stained cells showed intense
concentration of bright orange color within frag-
mented or condensed nuclei of VSMCs (Fig 7). 
Apoptosis of VSMCs was greatest within
aneurysmal aortas with 11.7 ± 1.5 cells/HPF, com-
pared with occlusive aortas with 3.3 ± 0.8 cells/HPF
(P < .05) and normal aortas with 3.75 ± 4.6
cells/HPF (P < .05; Table I). No significant differ-
ence was noted between normal and occlusive aortic
tissue for VSMC apoptosis. 
Immunohistochemical staining with an anti-
body that recognizes both the wild type and
mutant p53 protein was performed on representa-
tive sections of all aortic tissue, with ductal breast
carcinoma serving as the positive control. Strong
nuclear staining was observed in the positive con-
trol; however, no specific staining for the p53 anti-
body was noticed in the medial component of tis-
sue sections reviewed. Positive nuclear staining of
adventitial lymphocytes and rare mononuclear cells
was observed in multiple sections. The protein was
isolated, denatured, and electrophoresed on a 4%
to 20% Tris-glycine gel and blotted for p53. An
intense band at 53 kDa was detected in the control
lane (MCF-7). Only faint banding was observed
for p53 in aneurysmal and normal aorta samples.
Because of such scant expression, no significant
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Fig 1. α1-Actin antibody staining. A, Normal aorta (NL). Note the increased staining within the
medial layer and the uniformity of the VSMC; the luminal surface is towards upper right hand
corner. B, Occlusive aorta. Note the similar staining distribution; the luminal surface is towards
the right. C, AAA. Note the disrupted architecture within the medial layer and the inflammato-
ry cell and red blood cell infiltrate within the lower left corner; the luminal surface is towards the
upper right. (Original magnification of all tissue, ×100). AOD, Aortic occlusive disease. 
Table I. Aortic data: values* of average VSMC
apoptosis and VSMC density for each aortic subtype 
Aorta type N Apoptotic VSMC VSMC density
Aneurysmal 17 11.7 ± 1.5 271.8 ± 13.4
Occlusive 10 3.3 ± 0.8 278.2 ± 39.4
Normal 6 3.8 ± 1.4 291.0 ± 25.4
*Values are expressed as mean and standard error of the mean.
differences were observed between aortic sub-
types. Similar staining techniques were used for
identification of bcl-2. Mild to moderate positive
staining of lymphoid follicle–associated lympho-
cytes was present in positive control tissue. No
specific staining was detected for bcl-2 within the
medial layer of aortic sections reviewed. Rare pos-
itive nuclear staining of adventitial lymphocytes
was observed. 
Specimens were matched to certain patient char-
acteristics to assess the possible clinical significance of
VSMC apoptosis. No linear correlation between the
amount of VSMC apoptosis and the size of the
aneurysm or the age of the patient existed. 
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Fig 3. VSMC apoptosis staining in occlusive aorta. Cross-section of occlusive aortic tissue
(original magnification, ×100). The arrow shows typical apoptotic VSMC within medial layer.
Note the cholesterol plaque deposits on the lining of the endothelial layer. L, Luminal surface.
Fig 2. VSMC apoptosis staining in normal aorta. Cross-section of normal aortic tissue (orig-
inal magnification, ×60). The arrow shows typical apoptotic VSMC within medial layer. L,
Luminal surface. 
DISCUSSION
Human AAAs have distinct structural alterations
compared with any other arteriopathy. Pre-
dominance of destructive proteases, diminished
elastin content, and disruptive mechanical forces
have been shown to contribute to the degenerative
changes within the infrarenal aortic wall.12,14-19 Our
aim was to demonstrate that VSMC apoptosis was a
plausible mechanism of medial layer degeneration.
We observed an increase in apoptotic VSMCs and a
corresponding decrease in VSMC density within the
medial layer of AAA in contrast to occlusive and nor-
mal human aortas. Similar findings were reported by
Lopez-Candales et al,12 who documented a
decreased VSMC density, increased VSMC apoptot-
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Fig 4. VSMC apoptosis staining in aneurysmal aorta. Cross-section of aneurysmal aortic tis-
sue (original magnification, ×100). The arrow denotes typical apoptotic VSMC within the
medial layer. Nonlinear distribution of medial VSMC is apparent. L, Luminal surface.
Fig 5. High-power VSMC apoptosis staining. Cross-section of medial layer AAA tissue sample
(original magnification, ×400). The arrowhead is directed at positive nuclear staining for DNA
end-labeling in apoptotic cells. Note the similar positive staining cells towards the periphery. The
arrow points to the nonapoptotic cell. Note the lack of a dark brown–staining nucleus.
ic cells, and an increase in the percent of apoptotic
VSMCs within the aortic medial layer. Kondo et al20
also supported these results. They prospectively fol-
lowed induced aneurysm formation in cerebral arter-
ies of rats and demonstrated the presence of VSMC
apoptosis. In our study, VSMC apoptosis within the
medial layer was similar for occlusive and normal aor-
tas. Surprisingly, the structural integrity of the medi-
al layer in the atherosclerotic aorta is relatively unaf-
fected compared with the degenerative processes at
the intimal surface associated with plaque formation.
These findings suggest that a cellular signal mecha-
JOURNAL OF VASCULAR SURGERY
Volume 31, Number 3 Rowe et al 573
Fig 6. Colocalization of DNA end-labeling and α1-actin antibody. Cross-section of medial
layer AAA tissue sample (original magnification, ×400). The hollow arrowhead shows a typical
apoptotic nucleus with dark-brown staining. The solid arrowhead designates perinuclear pink
staining for VSMC. The arrow shows a cell with positive staining with α1-actin antibody, but neg-
ative apoptosis staining. Note the disorganized array of VSMC orientation. 
Fig 7. PI assay. Cross-section of medial layer normal aorta tissue sample under rhodamine flu-
orescence (original magnification, ×400). The arrow shows apoptotic VSMC with fragment-
ed, condensed nuclei and bright orange staining.
nism for VSMC apoptosis may influence aneurysmal
formation and progression. 
Controversy exists as to whether the observed
apoptotic cells are truly representative of the amount
of cells undergoing apoptosis. Geng and Libby10
contend that the apoptotic cell population observed
is falsely elevated by cells that underwent a pro-
grammed death long before the time of detection of
apoptosis. These mummified cells are postulated to
stain positively for fragmented DNA while awaiting
clearance from the tissue by phagocytosis, thus caus-
ing an inaccurate quantification of apoptosis. The
hypothesis of Geng and Libby may be correct, and
the overall counts of apoptotic cells may be elevated;
however, we contend that these mummified cells are
present within all of the tissue studied, thereby
negating the sampling error in a comparative study. 
With apoptosis present, questions are raised
about the initiating or regulatory factors involved in
the manipulation of the rate of cell suicide. Two
documented signal markers involved in apoptosis
regulation are p53 protein and bcl-2.12,21,22 The
p53 marker was first described as an apoptosis initia-
tor in cancer cells.23 Since that time, numerous
researchers have documented the universal role of
p53 in the apoptosis cycle of diverse tissues.12,22-25
In vascular biology, Bennett et al22 were able to
demonstrate that apoptosis in cultured VSMC
occurred through p53-dependent and p53-indepen-
dent pathways; Lopez-Candales et al12 found higher
levels of p53 protein within aneurysmal aortic tissue
when compared with normal human aortas through
reverse transcriptase. We were unable to conclusive-
ly demonstrate the differences in p53 protein within
aortic tissue using immunohistochemistry or protein
electrophoresis. In cells with positive staining for
p53, we observed predominately nuclear staining as
opposed to cytoplasmic staining reported by other
investigators.12 These findings are consistent with
Bennett et al22 who demonstrated that in vitro over-
expression of p53 protein by rat aortic VSMCs was
confined to nuclear staining. During the preparation
for Western blotting, extensive tissue mincing is
required. The inevitable inclusion of plasma proteins
within blood-tinged fresh specimens may have dilut-
ed the sample to the extent that it precluded accu-
rate isolation of scant p53 protein from the tissue.
Similar findings occurred when isolation of bcl-2, a
known inhibitor of apoptosis in various neoplastic
processes, was attempted.21 Perhaps, further investi-
gation should focus on specific prevention factors of
VSMC apoptosis rather than isolation of such elusive
markers. Initial data from our laboratory indicates
that vascular endothelial growth factor has a protec-
tive effect against ultraviolet radiation–induced
apoptosis in cultured VSMCs. 
No linear correlation was apparent between the
amount of VSMC apoptosis and the size of the AAA.
This could represent a distributional variation in the
area of aneurysmal tissue sampled or variations in the
rate of progression of medial degenerative changes.
Kondo et al20 prospectively followed induced
aneurysm formation in the cerebral arteries of rats.
When the aneurysmal arteries were closely exam-
ined, the greatest amount of VSMC apoptosis was
observed within the medial layer at the neck (the
transition zone) of the aneurysm as opposed to the
area of maximum diameter. Our samples were taken
from the anterolateral aneurysm wall where the
diameter was the greatest because of the ease of har-
vest and minimal interference with the proximal
anastomosis. Prospective comparison between these
two anatomic areas and meticulous documentation
of the progression rate may prove beneficial to fur-
ther investigation. Laplace’s law explains that for a
given pressure, tangential wall stress increased expo-
nentially as the radius of the tube enlarged. It is pos-
sible that the rate of AAA enlargement relates to
detected VSMC apoptotic events. Unfortunately,
our records and the referral pattern of patients with
significant AAA restricted that aspect of the study.
Also, most patients do not obtain the diagnosis of
AAA until it is large in size, thus complicating con-
struction of a longitudinal human study. 
As the aging process matures, degenerative
changes increase in multiple organ systems. This
theory is partly supported by the higher incidence of
AAA and atherosclerosis in the elderly population.
Thompson et al19 reasoned that an increase in age
corresponded with more structural degeneration,
leading to a cell population more susceptible to
apoptosis. Our data could not demonstrate a corre-
lation in VSMC apoptosis rates and age of the
patients in the AAA subset. 
CONCLUSION
Our study demonstrates that apoptosis of VSMCs
does play a role in large vessel tissue architecture at
the cellular level. When compared with normal aortic
tissue, VSMC density within the medial layer shows
a decreasing trend in diseased aortas (occlusive more
than aneurysm). Correspondingly, VSMC apoptosis
is significantly greater within the medial layer of
aneurysmal aortas when matched against normal and
occlusive aortas. Correlation of VSMC apoptosis in
aneurysmal disease with patient characteristics still
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warrants further investigation before any etiologic
postulates can be confirmed. Such information may
lead to novel therapeutic approaches in the preven-
tion and treatment of aortic disease.
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Dr Thomas S. Huber (Gainesville, Fla). Apoptosis is a
highly regulated mechanism of cell death controlled by
interaction of the cellular receptors, cytoplasmic and
nuclear gene products, and local cytokine and cellular
environment. Apoptosis has been recently incriminated in
a variety of processes, including aneurysms, atherosclero-
sis, and response of the vessel wall to injury. 
Notably, Thompson et al19 reported that the density
of smooth muscle cells was decreased within the AAAs and
that 30% of the smooth muscle cells stained positive for
their marker of apoptosis. Furthermore, the protein con-
centrations of p53, an inducer of apoptosis, were increased
four-fold in the aneurysmal tissue. Additionally, Sakaki et
al26 reported that smooth muscle cells within ruptured
intracranial aneurysms were significantly more degenerat-
ed and had a higher incidence of apoptotic bodies when
compared with intact aneurysms. 
You harvested aortic tissues from patients with
aneurysms who were undergoing aortoiliac bypass graft-
ing for occlusive disease and organ harvest for transplanta-
DISCUSSION
tion. You reported a decrease in the density of smooth
muscle cells within the aneurysmal tissue, although the
differences did not reach statistical significance. You
reported an increased incidence of apoptosis within the
aneurysmal tissue relative to the other two types, although
there was no difference among the aortic subtypes for the
two regulator proteins for apoptosis analyzed. Based on
the increased incidence of apoptosis and the decreased
density of VSMCs, they concluded that the structural
degeneration of the aortic tissue at the cellular level con-
tributes to aneurysmal formation. 
Although I am intrigued by the biologic phenomenon
of apoptosis and its potential role in vascular pathology, I
take exception to the authors’ conclusions. As noted, there
was no significant difference in the smooth muscle cell
density among the aortic subtypes; to propose that the
observed increased incidence of apoptosis contributes to
aneurysm formation is possible, although at best, a reach.
Clearly, the authors may be onto something very impor-
tant, but the descriptive nature of the study and the single
static image of the aortic tissue does not elucidate the
underlying mechanisms of a very complex process that
occurs over the course of a lifetime. 
How was the aortic tissue harvested at the time of
aneurysmal repair? I am somewhat bothered by studies in
which aneurysmal aortic tissue is harvested, then subse-
quently analyzed, in light of the degenerative aortic tissue
and the intraluminal debris frequently encountered. 
How do you interpret your findings in view of the ele-
gant study by Thompson et al,19 who reported a decreased
smooth muscle cell density and increased p53 levels with-
in the aneurysmal tissue? 
What do you hypothesize are the extracellular and intra-
cellular signals for apoptosis within the aneurysmal tissue? 
How do you explain your findings that no increased
evidence of apoptosis was identified within the aortic tis-
sue in patients with occlusive disease in light of the wealth
of studies incriminating apoptosis in atherosclerosis? 
Lastly, and perhaps most importantly, I would like you to
comment on the clinical relevance of the increased number
of apoptotic cells within the aneurysmal aortic tissue. Indeed,
it is unclear to me whether apoptosis leads to aneurysms or
vice-versa. In my fairly limited vascular surgery career, multi-
ple causes have been incriminated for aneurysms, including
copper metabolism, collagen, elastase, lysyl oxidase, inflam-
matory cytokines, and the metalloproteinases, although our
overall understanding has advanced little. 
Dr Rowe. First of all, in terms of the harvest, all of our
tissues were harvested within the operating room, and the
ones for molecular work were frozen in liquid nitrogen
immediately within the operating room so that we did not
have any delay in terms of decreasing our molecular con-
tent. For the paraffin-embedded specimens, we harvested
them and put them immediately within neutral-buffered
formalin and then transferred them to 70% alcohol. All of
the specimens were processed that way. 
In terms of the p53 marker, we did not identify a sig-
nificant difference within the p53 marker within our tis-
sue. I am well aware of the work by Dr Thompson and his
group, and they did perform a very elegant study. They
did note a small difference in p53 expression by protein
work. The way that their largest difference was expressed
was by doing a reverse transcriptase polymerase chain reac-
tion, in which the signal of the p53 was amplified to 35 to
40 times before they found a difference. I think that shows
that the p53 is in very scant amounts within the tissue and
that to have to multiply the expression of that to such
great levels shows that it may not have the exact signifi-
cance that we really think. 
In terms of the intracellular and extracellular signals, I
cannot really comment on that at this time. Research is
going to have to continue. Again, we have searched for the
bcl-2, p53, TNF-α; and our search probably has not been
as extensive as other laboratories, but so far no one is able
to conclude exactly which signal is occurring within the
aneurysmal tissue. 
In terms of the increase that we did not note within
our atherosclerotic tissue, I think the literature in terms of
apoptosis and atherosclerotic tissue points to apoptosis
occurring within the endothelial layer in plaque morpho-
logic features and intimal hyperplasia. The focus of our
research examined toward the medial layer of the aortic
tissue, and we did not see much difference in medial layer
apoptosis between vessels and normal vessels. 
Regarding the clinical significance, at this point we
believe that apoptosis does play a role. To say that it is the
sole cause would be somewhat exaggerated, but we do feel
that it plays a role. One study that seemed to stimulate us was
a study in rats where they artificially induced aneurysm for-
mation within the cerebral arteries and then followed these
rats. Once the rats were killed, the researchers looked at the
apoptotic rates within different samples of the aneurysmal tis-
sue, and they found the apoptosis to be greatest within the
transitional zone where the artery was just becoming
aneurysmal, as opposed to the segment where the maximal
diameter of the aneurysm was present. I thought that was
very interesting because that is saying that it is occurring at
the point where it is starting to change. Right now we are
currently harvesting our samples from not only the dome of
the aneurysm but also proximally and at the neck to see
whether we can find a difference within human tissue. 
The other key clinically will come from where we will
be able to not only just identify markers but also inhibit
the whole process or at least slow the aneurysmal progres-
sion. I think with aneurysmal disease it is going to be dif-
ficult to say that you can stop the formation, but once you
find someone with a small aneurysm, the question will be
whether you can inhibit the progression of disease. Right
now we are looking at different markers that are able to
slow down the rate of apoptosis within smooth muscle
cells. We have been able to identify a couple of growth fac-
tors, which (when placed in cell culture) will inhibit apop-
tosis. Will that become clinically significant? We hope so,
because if it is, then maybe we can take patients with a 3.5-
cm aneurysm, give them a particular growth factor, and
keep the progression rate at none. 
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